COMT Val 158 Met genotype influences neurodegeneration within dopamine-innervated brain structures

Efstathios D. Gennatas, Jeremy A. Cholfin, Juan Zhou, Richard K. Crawford, Daiki Sasaki, Anna Karydas, Adam L. Boxer, Stephen J. Bonasera, Katherine P. Rankin, Maria Luisa Gorno‐Tempini, Howard J. Rosen, Julia Krämer, Michael W. Weiner, Bruce L. Miller, William W. SeeleyNeurology 2012 · DOI

TL;DR

This study investigates how a common genetic variation in the COMT gene (Val158Met) influences brain degeneration in regions rich in dopamine. They found that carrying the "Val" variant of this gene is associated with greater gray matter loss in these dopamine-rich areas, particularly in patients with neurodegenerative diseases. This suggests that this genetic difference can exacerbate brain damage in these vulnerable regions.

What Problem Does This Paper Address?

Neurodegenerative diseases like Alzheimer's and frontotemporal dementia often present with significant variability in their anatomical presentation and severity. While some genetic factors are known to cause dementia, the role of genetic background in modifying the pattern or severity of injury in sporadic cases has received less attention. This paper focuses on the COMT Val158Met polymorphism, a common variation in a gene that plays a crucial role in dopamine metabolism. Dopamine is a key neurotransmitter involved in various brain functions, including cognition, emotion, and reward processing. The Val allele of this polymorphism is known to lead to faster dopamine breakdown, resulting in lower synaptic dopamine availability compared to the Met allele. The researchers aimed to determine if this difference in dopamine metabolism, influenced by COMT genotype, could contribute to the heterogeneous patterns of neurodegeneration observed in dopamine-innervated brain structures.

Methods

The study employed a combination of neuroimaging and genetic analysis on a cohort of 252 individuals, including healthy controls and patients with Alzheimer disease (AD), behavioral variant frontotemporal dementia (bvFTD), and semantic dementia (SemD).

  • COMT Genotyping: The COMT Val158Met single nucleotide polymorphism (SNP) was genotyped using a standard TaqMan assay.
  • Structural MRI: High-resolution T1-weighted structural MRI scans were acquired using a volumetric MPRAGE sequence.
  • Voxel-Based Morphometry (VBM): This is the core neuroimaging analysis technique. VBM allows for the statistical comparison of brain structure at the voxel level across groups. The MRI images were preprocessed using the VBM5 toolbox within SPM5, including segmentation into gray matter, normalization to a standard anatomical space (Montreal Neurological Institute), and smoothing. A general linear model was used to assess the relationship between COMT genotype (specifically, Val allele dosage) and gray matter intensity, while controlling for factors like diagnosis, age, sex, and total intracranial volume (TIV).
  • Statistical Analyses: Whole-brain voxel-wise regression analyses were performed. Regions of interest were identified based on a priori hypotheses about dopamine-innervated areas. Follow-up stepwise linear regression analyses were conducted to confirm findings and explore the influence of potential confounders. Multivariate analyses were also used to examine the direct effect of COMT genotype on cognitive and neuropsychiatric scores.

Datasets

The study utilized data from a cohort of 252 subjects recruited from the University of California, San Francisco (UCSF) Memory and Aging Center (MAC) database. This cohort included:

  • Healthy controls
  • Patients diagnosed with Alzheimer disease (AD)
  • Patients diagnosed with behavioral variant frontotemporal dementia (bvFTD)
  • Patients diagnosed with semantic dementia (SemD)

The data included structural MRI scans, COMT genotype information, and cognitive/neuropsychiatric assessments.

Key Insights and Ideas

  • Dose-Dependent Atrophy: The most striking finding is that increasing "Val" allele dosage in the COMT gene is associated with a dose-dependent decrease in gray matter intensity in specific dopamine-innervated brain regions. This suggests a direct link between genetic variation influencing dopamine metabolism and structural brain changes.
  • VTA Anomaly: Counterintuitively, patients with at least one "Met" allele (which leads to higher dopamine availability) showed increased gray matter volume in the ventral tegmental area (VTA) compared to genotype-matched controls. This suggests a potential compensatory mechanism or a different response to disease in individuals with higher dopamine levels.
  • Indirect Effect on Cognition: While COMT genotype directly influences brain structure in dopamine-related regions, it does not appear to have a direct effect on cognitive or behavioral function when diagnosis is accounted for. This implies that the genetic influence on brain structure is the primary mechanism, which then indirectly impacts cognition and behavior.
  • Structural Integrity Predicts Function: Atrophy in the identified COMT-related brain regions (like the dorsolateral prefrontal cortex and ventral tegmental area) was correlated with cognitive and behavioral deficits. This reinforces the idea that the structural changes driven by COMT genotype have functional consequences.

Key Results

  • Negative Correlation with Val Dose: Whole-brain regression analyses identified 6 regions where increasing Val allele dosage was associated with decreasing gray matter intensity (p < 0.001, uncorrected). These included the ventral tegmental area (VTA), ventromedial prefrontal cortex (vmPFC), bilateral dorsal midinsula/frontal operculum (dMI/FO), left dorsolateral prefrontal cortex (dlPFC), and right ventral striatum (VStr).
  • Positive Correlation with Val Dose: The left hippocampus showed a positive correlation, meaning increasing Val allele dosage was associated with increasing gray matter intensity.
  • VTA Volume in Met Carriers: Patients with at least one Met allele had significantly higher VTA volumes compared to genotype-matched controls. This effect was not observed in Val/Val carriers.
  • No Direct Genotype Effect on Cognition/Behavior: Multivariate analyses showed no direct effect of COMT genotype on cognitive or behavioral scores in patients, even after controlling for diagnosis and other confounders.
  • Regional Atrophy Correlates with Deficits: Stepwise linear regression revealed that atrophy in COMT-related regions predicted cognitive and behavioral impairments. For instance, dlPFC atrophy was linked to cognitive deficits, and vmPFC atrophy to behavioral disinhibition.

Limitations and Future Work

  • Sample Size Limitations: The study acknowledges that dividing the large cohorts into smaller genotype-specific groups for each clinical syndrome limited the ability to explore potential interactions (e.g., sex-specific influences). Future larger studies are needed to confirm these findings and explore such interactions.
  • VTA Anomaly Requires Confirmation: The unexpected finding of increased VTA volume in Met carriers requires further investigation and confirmation in larger datasets. The authors propose a hypothesis that disease-related feedback on VTA neurons might lead to hypertrophy, which is more pronounced in individuals with higher dopamine availability.
  • Mechanistic Understanding: While the study establishes a correlation, the precise mechanisms by which synaptic dopamine availability modulates neurodegeneration require further research.
  • Pharmacological Implications: The findings suggest that patients with the Val allele might benefit from pharmacological strategies that increase synaptic dopamine availability, such as COMT inhibitors. This opens avenues for future therapeutic research.
  • Broader Genetic Influence: The authors suggest that future studies could explore the influence of other neuromodulatory gene polymorphisms on brain structures and disease mechanisms, potentially clarifying disease heterogeneity and identifying new therapeutic targets.

Summary updated

Abstract

The results are consistent with the hypothesis that increased synaptic DA catabolism promotes neurodegeneration within DA-innervated brain regions.
BibTeX
@inproceedings{gennatas2012comt,
  author = {Efstathios D. Gennatas and Jeremy A. Cholfin and Juan Zhou and Richard K. Crawford and Daiki Sasaki and Anna Karydas and Adam L. Boxer and Stephen J. Bonasera and Katherine P. Rankin and Maria Luisa Gorno‐Tempini and Howard J. Rosen and Julia Krämer and Michael W. Weiner and Bruce L. Miller and William W. Seeley},
  title = {{COMT Val <sup>158</sup> Met genotype influences neurodegeneration within dopamine-innervated brain structures}},
  booktitle = {Neurology},
  year = {2012},
  doi = {10.1212/wnl.0b013e3182574fa1},
}
Figure